I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Which has more volatility and risk, IMAB or IMCR?

I-Mab has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Is IMAB or IMCR more profitable?

I-Mab has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Immunocore's return on equity of -5.40% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	-19.65%	-18.58%
Immunocore	-5.70%	-5.40%	-1.93%

Do analysts recommend IMAB or IMCR?

I-Mab presently has a consensus target price of $7.00, suggesting a potential upside of 50.54%. Immunocore has a consensus target price of $56.89, suggesting a potential upside of 61.30%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunocore	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Does the media favor IMAB or IMCR?

In the previous week, Immunocore had 2 more articles in the media than I-Mab. MarketBeat recorded 4 mentions for Immunocore and 2 mentions for I-Mab. Immunocore's average media sentiment score of 0.93 beat I-Mab's score of 0.73 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation & earnings, IMAB or IMCR?

I-Mab has higher earnings, but lower revenue than Immunocore.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$22.23M	N/A	N/A
Immunocore	$310.20M	5.73	-$51.09M	-$0.40	-88.18

Do institutionals and insiders hold more shares of IMAB or IMCR?

38.4% of I-Mab shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 10.4% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Immunocore beats I-Mab on 8 of the 13 factors compared between the two stocks.